Solanezumab Doesn't Affect Cognitive Decline in Alzheimer's

Share this content:
Solanezumab Doesn't Affect Cognitive Decline in Alzheimer's
Solanezumab Doesn't Affect Cognitive Decline in Alzheimer's

FRIDAY, Jan. 26, 2018 (HealthDay News) -- For patients with mild Alzheimer's disease, solanezumab administered every four weeks does not alter cognitive decline, according to a study published in the Jan. 25 issue of the New England Journal of Medicine.

Lawrence S. Honig, M.D., Ph.D., from Columbia University Medical Center in New York City, and colleagues conducted a double-blind, placebo-controlled trial involving patients with mild dementia due to Alzheimer's disease. A total of 2,129 patients were enrolled and randomized to receive solanezumab (400 mg; 1,057 patients) or placebo (1,072 patients) intravenously every four weeks for 76 weeks.

The researchers found that the mean change from baseline in the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale score was 6.65 and 7.44 in the solanezumab and placebo groups, respectively, with no significant difference between the groups at week 80 (difference, −0.8; 95 percent confidence interval, −1.73 to 0.14; P = 0.1). The change from baseline in the Mini-Mental State Examination score was −3.17 and −3.66 in the solanezumab and placebo groups, respectively.

"Solanezumab at a dose of 400 mg administered every four weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Critics Demand Stop to 'Guinea Pig' Sepsis Clinical Trial

Critics Demand Stop to 'Guinea Pig' Sepsis Clinical ...

Clovers trial seeks to determine which IV fluids, vasopressors combo works best to curb sepsis

Education Can Up Emotional Intelligence in Residents

Education Can Up Emotional Intelligence in Residents

Increase in total EI median scores, stress management composite score after intervention

Cancer-Related Gene Variations Frequently Reclassified

Cancer-Related Gene Variations Frequently Reclassified

24.9 percent of variants of uncertain significance were reclassified at a single commercial laboratory

is free, fast, and customized just for you!




Already a member?

Sign In Now »